Navigation Links
Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
Date:8/6/2008

us organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

Genzyme Safe Harbor Statement

This press release contains forward-looking statements, including without limitation, statements concerning mipomersen's safety and benefits for patients with high cholesterol, the development plan for mipomersen and FDA's requirements for its approval. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the timing of further discussions with FDA regarding the approval of mipomersen; the timing and content of submissions to and decisions made by the FDA relating to mipomersen; further analysis of clinical trial data; the results of other studies; the actual efficacy and safety of mipomersen; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) is a registered trademark of Genzyme Corporation. All rights reserved.

Isis Safe Harbor Statement

This press release includes forward-looking statements regarding Isis' collaboration with Genzyme Corporation, its financial and business developme
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Isis Complete Licensing of Mipomersen
2. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. Genzyme Announces Presentation of New Positive Data on Carticel(R)
5. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
6. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
7. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
10. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced ... Cytogenetics Market 2014-2018" report to their ... ,Molecular Cytogenetics involves the study of chromosomes ... and functions of genes and chromosomes. It ...
(Date:9/18/2014)... Sept. 18, 2014  LABSCO, the leading ... and products to hospitals, physician office laboratories ... amended distributorship agreement with Sysmex America.  This ... instruments, including the Sysmex XS-1000 i ™, ... and XN-Series Automated Hematology Analyzers. ...
(Date:9/18/2014)... -- According to the new research ... Warming & Cooling), Application (Acute & Perioperative Care, ... & Paramedical Staff) - Global Forecasts & Trends ... global Temperature Management Market over the forecast period ... to reach $2.5 Billion by 2019 at CAGR ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4
... EyeScience(TM) ( www.eyescience.com ) announced today that ... and Dry Eye Formula(TM) are the only ... from their offices and through mass market retail. This announcement ... growing demand for the most complete eye vitamins available for ...
... (Nasdaq: HOLX ) today announced that Jack Cumming, Chairman, ... London on Tuesday, December 1, 2009, at 11:15am (GMT). ... audio webcast of Hologic,s investor presentation on the investor section ... An archive of the presentation will be available for replay ...
Cached Medicine Technology:EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 2EyeScience(TM) Announces New Program to Improve Patient Compliance and Practice Profits 3
(Date:9/19/2014)... Business Insider Australia Rates Appy Pie as a ... Appy Pie was also listed as one of the ... Yahoo . , Appy Pie a leading cloud based DIY ... minutes and it requires no coding knowledge or previous experience ... mobile operating systems, the apps created using their platform are ...
(Date:9/19/2014)... CA (PRWEB) September 19, 2014 The ... a special promotion for new patients. Throughout the month of ... dental exam with dental X-rays for just $69. A complimentary ... patients to get their teeth and gums checked and meet ... are among the best ways to protect oral health. According ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. 18, ... got a flu shot last year, so U.S. health officials ... vaccinated for the coming flu season. "It,s really unfortunate ... flu they could get," said Dr. Thomas Frieden, director of ... morning news conference. The result is lost days from ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
(Date:9/19/2014)... LENEXA, Kan. (PRWEB) September 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for St. John’s Episcopal Hospital in Far Rockaway, N.Y. ... B. E. Smith has recently placed more than 900 ... Hospital is a faith-based, full service community hospital serving ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... to the brain can be devastating. When brain cells die, ... glutamate floods the surrounding areas, overloading the cells in its ... swathes of tissue. ,Glutamate is always present ... gaps between cells. But when this chemical is released by ...
... infections in parts of Cambodia is being extended to an ... 40,000 residents, an expert said. ,Although malaria-infected mosquitoes ... the real source of the disease is people, some of ... time without showing clear symptoms. ,Moheli island, the ...
... responsible for staphylococcus infections can kill infected patients in ... by the name of PVL or otherwise called Panton ... and harm the healthy tissue as well. ... infections. This is normally found in the skin or ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... Center researchers have identified an approach to enhance the ... shown impressive efficacy in the treatment of chronic myelogenous ... a cancer of the bone marrow caused by a ... common forms of leukemia. Imatinib mesylate (Gleevec) is a ...
... is probing the link between breast density and its implication ... novel study on 1,112 women has brought to the fore, ... with dense breasts. The study revealed that, those with dense ... breast cancer, compared to women with fatty tissue in the ...
Cached Medicine News:Health News:New Method May Treat Brain Injuries 2Health News:Chinese Scientists Take Malaria Fight to Africa 2Health News:New Strategy for the Treatment of CML 2Health News:New Strategy for the Treatment of CML 3
Yasargil clip applying forceps Mini. Stainless steel jaw....
Round tip, sharp all around, angled....
Operating microscope with motorized zoom and variable focus up to 405 mm....
... microscope provides surgeons with brighter, crisper, magnified ... ideal for many minimally invasive spine procedures. ... every point of contact. The first graphical ... microscope allows intuitive user guidance similar to ...
Medicine Products: